



Trendlines Portfolio Company EcoPhage Receives U.S. EPA Approval for GoldenEco[®], Its Phage-Based Biopesticide for Bacterial Plant Diseases

- *The EPA approval marks a major regulatory milestone, opening the commercial launch pathway in the U.S. market for GoldenEco[®]*
- *GoldenEco[®] provides tomato and pepper growers with a targeted, sustainable biological alternative to conventional chemical and metal-based treatments*

Misgav, Israel – 17 September 2026 – The Trendlines Group Ltd. (SGX: 42T; OTCQX: TRNLY), an investment group focused on agrifood and medtech innovation, is pleased to announce that portfolio company **EcoPhage Ltd. (“EcoPhage”)**, a leader in sustainable phage-based biopesticides, has received **U.S. Environmental Protection Agency (“EPA”)** approval for GoldenEco[®]. GoldenEco[®] is a targeted biopesticide developed to address destructive bacterial diseases in tomatoes and peppers caused by *Xanthomonas* and *Pseudomonas*. The approval opens the commercialization pathway for GoldenEco[®] in the United States, subject to applicable state registrations and other requirements.

Bacterial diseases remain a major operational challenge for tomato and pepper growers, with conventional crop management relying heavily on chemical and metal-based treatments. Heightened regulatory scrutiny, environmental concerns, pathogen resistance, and rising demand for sustainable farming practices are driving the market toward effective biological solutions. GoldenEco[®] leverages EcoPhage’s proprietary bacteriophage technology to deploy naturally occurring phages that specifically target and destroy bacterial pathogens without chemical residues.

Trendlines’ Executive Director and CEO Haim Brosh commented: “This regulatory milestone demonstrates EcoPhage’s technical leadership and its capability to execute a successful regulatory strategy toward commercial entry in the U.S. market.”

“We believe this EPA approval significantly strengthens EcoPhage’s growth trajectory and long-term value creation potential in sustainable crop protection. Trendlines remains a committed shareholder supporting EcoPhage’s commercialization efforts,” added Trendlines’ EVP Head of Agrifood, Nitza Kardish, PhD.

GoldenEco[®] represents the first product in EcoPhage’s platform to achieve U.S. commercial entry, proving the company’s ability to advance phage-based biopesticides from research and development through rigorous regulatory review.

Guy Elitzur, CEO of EcoPhage, commented on the approval: “Receiving EPA approval for GoldenEco[®] is a major achievement for EcoPhage and an important milestone in our

commercialization strategy. After years of research, development, field testing, and regulatory work, we are now ready to bring GoldenEco® to U.S. growers. This approval validates the strength of our technology platform and represents an important step toward providing growers with new biological tools to manage bacterial diseases in high-value crops.”

Following the EPA approval, EcoPhage will execute its commercial roll-out by collaborating with U.S. commercial partners, distributors, and growers to prepare for market development and distribution.

-The End-

About EcoPhage Ltd.

EcoPhage is an agricultural biotechnology company developing innovative biological solutions for the control of bacterial plant diseases. Based on its proprietary phage discovery and development platform, EcoPhage develops targeted, natural, non-GMO, and zero-residue biopesticides designed to provide effective disease management across a broad range of crops. The company is advancing a growing pipeline of phage-based products targeting important bacterial diseases and is focused on delivering sustainable solutions that support growers and the future of modern agriculture.

About The Trendlines Group Ltd.

The Trendlines Group (SGX: 42T; OTCQX: TRNLY) invests in and develops innovations in agrifood and medtech, transforming early-stage technologies into impactful businesses. With operations in Israel and Singapore, Trendlines combines capital, expertise, and strategic partnerships to drive growth, advance global sustainability, and create long-term value for shareholders.

This press release has been reviewed by the Company’s sponsor, PrimePartners Corporate Finance Pte. Ltd. (the “Sponsor”). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the “Exchange”) and the Exchange assumes no responsibility for the contents of this press release, including the correctness of any of the statements or opinions made or reports contained in this press release.

The contact person for the Sponsor is Mr. Shervyn Essex, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.

Investor Contact Information

Israel:

Shira Zimmerman, The Trendlines Group
shira@trendlines.com
Tel: +972.72.260.7000

Singapore:

Kamal Samuel, Financial PR
kamal@financialpr.com.sg
Rishika Tiwari, Financial PR
rishika@financialpr.com.sg
Tel: +65.6438.2990